Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IBM NASDAQ:NVDA NYSE:RH OTCMKTS:RHHBY OTCMKTS:RHHVF NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBMInternational Business Machines$256.53+0.2%$260.31$202.87▼$296.16$238.07B0.714.66 million shs614,080 shsNVDANVIDIA$168.03-0.2%$172.94$86.62▼$184.48$4.08T2.1236.42 million shs32.26 million shsRHRH$230.33-4.4%$216.55$123.03▼$457.26$4.31B2.151.29 million shs138,804 shsRHHBYRoche$42.39-0.2%$40.24$34.10▼$44.31$269.74B0.472.23 million shs90,200 shsRHHVFRoche$336.13-1.4%$322.07$269.80▼$354.19N/AN/A8,369 shs69 shsRXRXRecursion Pharmaceuticals$4.61-0.3%$5.38$3.79▼$12.36$1.99B0.9124.01 million shs2.76 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBMInternational Business Machines+3.11%+5.18%+5.92%-7.23%+27.63%NVDANVIDIA+0.77%-3.37%-7.86%+16.91%+63.68%RHRH-4.22%+6.63%+11.85%+27.09%-3.11%RHHBYRoche-1.23%+4.17%+11.09%+3.41%+4.89%RHHVFRoche-0.94%+4.67%+11.72%+3.61%+5.68%RXRXRecursion Pharmaceuticals+0.22%-1.70%-13.81%-15.23%-21.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBMInternational Business Machines$256.53+0.2%$260.31$202.87▼$296.16$238.07B0.714.66 million shs614,080 shsNVDANVIDIA$168.03-0.2%$172.94$86.62▼$184.48$4.08T2.1236.42 million shs32.26 million shsRHRH$230.33-4.4%$216.55$123.03▼$457.26$4.31B2.151.29 million shs138,804 shsRHHBYRoche$42.39-0.2%$40.24$34.10▼$44.31$269.74B0.472.23 million shs90,200 shsRHHVFRoche$336.13-1.4%$322.07$269.80▼$354.19N/AN/A8,369 shs69 shsRXRXRecursion Pharmaceuticals$4.61-0.3%$5.38$3.79▼$12.36$1.99B0.9124.01 million shs2.76 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBMInternational Business Machines+3.11%+5.18%+5.92%-7.23%+27.63%NVDANVIDIA+0.77%-3.37%-7.86%+16.91%+63.68%RHRH-4.22%+6.63%+11.85%+27.09%-3.11%RHHBYRoche-1.23%+4.17%+11.09%+3.41%+4.89%RHHVFRoche-0.94%+4.67%+11.72%+3.61%+5.68%RXRXRecursion Pharmaceuticals+0.22%-1.70%-13.81%-15.23%-21.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBMInternational Business Machines 2.47Hold$268.754.76% UpsideNVDANVIDIA 2.93Moderate Buy$207.4223.44% UpsideRHRH 2.41Hold$273.4718.73% UpsideRHHBYRoche 2.57Moderate BuyN/AN/ARHHVFRoche 0.00N/AN/AN/ARXRXRecursion Pharmaceuticals 2.40Hold$7.2557.44% UpsideCurrent Analyst Ratings BreakdownLatest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025NVDANVIDIACitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$210.00 ➝ $200.009/8/2025RHRHWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$275.00 ➝ $295.009/8/2025RHRHTelsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$255.009/4/2025NVDANVIDIAJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$215.009/3/2025RHRHCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$200.00 ➝ $233.008/28/2025NVDANVIDIAKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$215.00 ➝ $230.008/28/2025NVDANVIDIAOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$200.00 ➝ $225.008/28/2025NVDANVIDIASanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$185.00 ➝ $225.008/28/2025NVDANVIDIACitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$190.00 ➝ $210.008/28/2025NVDANVIDIACraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$195.00 ➝ $245.008/28/2025NVDANVIDIADA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$135.00 ➝ $195.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBMInternational Business Machines$62.75B3.80$16.02 per share16.01$29.62 per share8.66NVDANVIDIA$130.50B31.29$3.08 per share54.62$3.25 per share51.70RHRH$3.18B1.36$16.46 per share13.99($8.79) per share-26.20RHHBYRoche$68.73B3.92$3.26 per share13.02$6.46 per share6.56RHHVFRocheN/AN/AN/AN/AN/AN/ARXRXRecursion Pharmaceuticals$58.84M33.98N/AN/A$2.61 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBMInternational Business Machines$6.02B$6.1641.5822.113.839.11%37.62%7.08%10/22/2025 (Estimated)NVDANVIDIA$72.88B$3.5147.8842.221.2152.41%101.74%70.72%11/19/2025 (Estimated)RHRH$72.41M$4.2054.7916.700.732.57%-67.71%2.60%9/11/2025 (Estimated)RHHBYRoche$9.40BN/A0.0014.132.37N/AN/AN/AN/ARHHVFRocheN/A$10.8131.09∞N/AN/AN/AN/AN/ARXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q2 2026RHRH$3.18N/AN/AN/A$906.58 millionN/A8/27/2025Q2 2026NVDANVIDIA$1.01$1.05+$0.04$1.08$45.65 billion$46.74 billion8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million7/23/2025Q2 2025IBMInternational Business Machines$2.65$2.80+$0.15$2.31$16.58 billion$16.98 billion6/12/2025Q1 2026RHRH-$0.07$0.13+$0.20$0.40$817.66 million$813.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBMInternational Business Machines$6.722.62%N/A109.09%30 YearsNVDANVIDIA$0.040.02%N/A1.14%1 YearsRHRHN/AN/AN/AN/AN/ARHHBYRoche$0.872.05%N/AN/AN/ARHHVFRoche$7.802.32%N/A72.16%N/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/27/2025NVDANVIDIAquarterly$0.010.02%9/11/20259/11/202510/2/20257/23/2025IBMInternational Business MachinesQuarterly$1.682.78%8/8/20258/8/20259/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBMInternational Business Machines2.000.910.87NVDANVIDIA0.084.213.60RHRHN/A1.370.29RHHBYRoche0.851.481.20RHHVFRocheN/AN/AN/ARXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBMInternational Business Machines58.96%NVDANVIDIA65.27%RHRH90.17%RHHBYRocheN/ARHHVFRoche29.01%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipIBMInternational Business Machines0.18%NVDANVIDIA4.17%RHRH27.00%RHHBYRocheN/ARHHVFRocheN/ARXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBMInternational Business Machines293,400929.40 million927.72 millionOptionableNVDANVIDIA36,00024.30 billion23.29 billionOptionableRHRH6,34018.73 million13.67 millionOptionableRHHBYRoche103,2496.36 billionN/ANot OptionableRHHVFRoche103,605N/AN/ANot OptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableRXRX, IBM, RH, RHHBY, RHHVF, and NVDA HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8 at 9:01 PM | seekingalpha.comRussell Investments Group Ltd. Has $206,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 4, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comJump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRXAugust 29, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 AcquisitionAugust 28, 2025 | insidermonkey.comRecursion to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLCAugust 25, 2025 | marketbeat.comNeedham Maintains Buy Rating on Recursion (RXRX)August 24, 2025 | msn.comThe Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to ExplodeAugust 23, 2025 | fool.comRecursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.August 23, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Caught a Cold This WeekAugust 22, 2025 | fool.comRecursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025August 22, 2025 | finance.yahoo.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of StockAugust 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of SharesAugust 21, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's WhyAugust 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 SharesAugust 20, 2025 | insidertrades.comEverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comLPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comRecursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment DataAugust 19, 2025 | seekingalpha.comLiontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)August 18, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.August 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025IBM: The Last Time This Happened, the Stock Rallied 35%By Sam Quirke | August 12, 2025Palantir’s Soaring Valuation—Justified or Overhyped?By Chris Markoch | August 14, 2025Is Reddit Stock Too Hot, or Just Right?By Sam Quirke | August 17, 2025Arista Networks: Cashing In as the Tollbooth for AI TrafficBy Jeffrey Neal Johnson | August 15, 2025RXRX, IBM, RH, RHHBY, RHHVF, and NVDA Company DescriptionsInternational Business Machines NYSE:IBM$256.53 +0.44 (+0.17%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.International Business Machines Corporation, together with its subsidiaries, provides integrated solutions and services worldwide. The company operates through Software, Consulting, Infrastructure, and Financing segments. The Software segment offers a hybrid cloud and AI platforms that allows clients to realize their digital and AI transformations across the applications, data, and environments in which they operate. The Consulting segment focuses on skills integration for strategy, experience, technology, and operations by domain and industry. The Infrastructure segment provides on-premises and cloud based server, and storage solutions, as well as life-cycle services for hybrid cloud infrastructure deployment. The Financing segment offers client and commercial financing, facilitates IBM clients' acquisition of hardware, software, and services. The company has a strategic partnership to various companies including hyperscalers, service providers, global system integrators, and software and hardware vendors that includes Adobe, Amazon Web services, Microsoft, Oracle, Salesforce, Samsung Electronics and SAP, and others. The company was formerly known as Computing-Tabulating-Recording Co. International Business Machines Corporation was incorporated in 1911 and is headquartered in Armonk, New York.NVIDIA NASDAQ:NVDA$168.03 -0.28 (-0.17%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.RH NYSE:RH$230.32 -10.67 (-4.43%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RH, together with its subsidiaries, operates as a retailer in the home furnishings market. The company offers products in various categories, including furniture, lighting, textiles, bathware, décor, outdoor and garden, baby, child, and teen furnishings. It provides its products through rh.com, rhbabyandchild.com, rhteen.com, rhmodern.com, and waterworks.com online channels, as well as operates RH Galleries, RH outlet stores, RH Guesthouse, and Waterworks showrooms in the United States, Canada, the United Kingdom, and Germany. The company was formerly known as Restoration Hardware Holdings, Inc. and changed its name to RH in January 2017. RH was incorporated in 2011 and is headquartered in Corte Madera, California.Roche OTCMKTS:RHHBY$42.39 -0.08 (-0.19%) As of 10:10 AM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Roche OTCMKTS:RHHVF$336.13 -4.63 (-1.36%) As of 10:07 AM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Recursion Pharmaceuticals NASDAQ:RXRX$4.61 -0.02 (-0.32%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Take the Money and Run: Strategy Stock Looks Tapped Out Why CAVA Is the Dip Buy to Outperform Chipotle What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave Stock MarketBeat Week in Review – 09/01 - 09/05 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
